Savara (SVRA) Expected to Announce Earnings on Thursday

Savara (NASDAQ:SVRA) is projected to issue its quarterly earnings data before the market opens on Thursday, March 6th. Analysts expect the company to announce earnings of ($0.11) per share for the quarter.

Savara Stock Performance

Shares of SVRA stock opened at $2.47 on Thursday. The firm’s 50 day moving average price is $2.89 and its 200-day moving average price is $3.51. The company has a debt-to-equity ratio of 0.13, a quick ratio of 17.70 and a current ratio of 17.70. Savara has a one year low of $2.44 and a one year high of $5.70. The firm has a market cap of $423.90 million, a P/E ratio of -5.74 and a beta of 0.63.

Analysts Set New Price Targets

SVRA has been the topic of several recent analyst reports. HC Wainwright decreased their price objective on shares of Savara from $10.00 to $6.00 and set a “buy” rating on the stock in a report on Wednesday, November 13th. JMP Securities restated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a report on Thursday, December 19th. Evercore ISI reaffirmed an “in-line” rating and set a $5.00 target price (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. Finally, Wells Fargo & Company started coverage on shares of Savara in a research note on Friday, December 20th. They set an “overweight” rating and a $8.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $9.86.

Insider Activity at Savara

In related news, CEO Matthew Pauls sold 54,702 shares of the stock in a transaction on Monday, December 16th. The shares were sold at an average price of $3.31, for a total value of $181,063.62. Following the transaction, the chief executive officer now directly owns 1,536,379 shares of the company’s stock, valued at $5,085,414.49. This trade represents a 3.44 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 5.13% of the company’s stock.

About Savara

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.